Daxor Corporation
corporate_fare Company Profile
Daxor Corporation (NASDAQ:DXR) is a publicly traded company in the Unknown sector. Wiseek has independently scored 9 items for DXR at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-06-02, rated 8/10. Across its 9 most recent items scored 7 or higher, the top rating is 8/10, with 7 rated 8 or above. Recent SEC coverage for DXR spans 40-8F-2/A, 40-8F-2, 8-K, 424B4.
Recent high-impact activity:
- Daxor Wins Patent for Remote Blood Volume Monitor, Expanding Diagnostic Capabilities
- Daxor Seeks Deregistration as Investment Company, Gaining Operational & Capital Flexibility
- Daxor Launches New BVA Program at High-Volume Ohio Cardiology Center, Boosting Customer Footprint
- New Clinical Data Validates Daxor's Blood Volume Analyzer as Uniquely Accurate
- Daxor to Unveil Portable BVA at ACC.26, Citing 56% Readmission Drop & 82% Mortality Reduction
Financial Snapshot
Short Interest & Short Volume
1.00 days to coverFINRA reported short interest of 2,331 shares in DXR as of the September 15, 2026 settlement, a 293.8% increase from the prior period — about 1.0 days to cover at its recent average daily volume. On October 2, 2026, 16.8% of DXR volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.